Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The list of potential of Buyers

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 22, 2022 12:53pm

139 Views

Post# 35187423

RE:RE:RE:RE:The list of potential of Buyers

As noted in an earlier posting ONCY's pelareorep down regulates HIF-1alpha, which is a sigificant inducer of TME hypoxia, as well as a down-regulator of the enzyme adenosine, which is a potent TME immunosuppressant, thus making ONCY's pelareorep a logical acquisition target for Pfizer.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China